A second phase I trial of FGLL.
Latest Information Update: 13 Dec 2011
Price :
$35 *
At a glance
- Drugs FGLL (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors ENKAM Pharmaceuticals A/S
- 13 Dec 2011 Status changed from planning to discontinued.
- 22 Feb 2008 New trial record.